期刊文献+

氨氯地平联合阿托伐他汀钙治疗冠心病合并高血压的分析 被引量:4

下载PDF
导出
摘要 目的探讨药物治疗冠心病合并高血压的临床疗效。方法选取某院2014年5月~2015年5月收治的冠心病合并高血压患者90例作为研究对象,对其临床资料进行回顾性分析。按照治疗药物的不同将所有患者分为对照组和观察组,各45例,其中对照组治疗药物为硝苯地平缓释片,观察组治疗药物为氨氯地平联合阿托伐他汀钙,对比两组临床疗效、血压以及血脂等情况。结果观察组治疗总有效率为91.1%,明显高于对照组80.0%,对比差异有统计学意义(P〈0.05);两组治疗前收缩压与舒张压对比差异不明显(P〉0.05),治疗后观察组收缩压为(125.39±21.96)mm Hg,舒张压为(67.35±11.52)mm Hg,低于对照组(140.13±23.51)mm Hg、(74.28±13.77)mm Hg,对比差异明显(P〈0.05);两组治疗前HDL-C、LDL-C、TC以及TG对比差异不明显(P〉0.05),治疗后观察组明显低于对照组(P〈0.05)。结论对于冠心病并高血压患者要采取有效药物治疗,以减少心脑血管发病风险,改善预后,控制血压,推荐应用氨氯地平联合阿托伐他汀钙治疗。
作者 杨璐
出处 《中国处方药》 2015年第10期79-80,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献6

二级参考文献28

  • 1Czemichow S, Zanchetti A, Turnbull F , et at. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major car?diovascular events according to baseline blood pressure: meta-analysis of randomized trials(J). J Hypertens ,2011 ;29(1) :4-16.
  • 2Conroy RM, Pyooraalaa K, Fitzgerald AP , et at. Estimation of ten -year risk of fatal cardiovascular disease in Europe: the SCORE project[J] . Eur Heart J ,2003 ;24(11) :987-1003.
  • 3De Backer G, Petrella JR, Goudev AR, et at. Design and methodology of POWER, an open-label observation of the effect of primary care interven- tions on total cardiovascular risk in patients with hypertension[J]. Fun?dam Clin Phannacol,2013;27(2) :210-5.
  • 4Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of differentblo,?d-pressure-Iowering regimens on major cardiovas?cular events: results of prospectively designed overviews of randomised trialsj J]. Lancet ,2003 ;362(9395) : 1527 -35.
  • 5Ambrosioni E, Bombelli M, Cerasola G, et al. Ambulatory monitoring of systolic hypertension in the elderly: eprosartanlhydrochlorothiazide com?pared with losartanlhydrochlorothiazide(INSIST trial)[J] . Adv Ther, 2010 ;27(6) :365-80.
  • 6Guallar E, Banegas JR, Blasco-Colmenares E, et at. Excess risk attributa?ble to traditional cardiovascular risk factors in clinical practice settings across Europe The EURIKA Study[J] . BMC Public Health, 2011 ; 11 : 704.
  • 7Xu FY , Yang B, Shi D, et al. Antihypertensive effects and safety of epro?sartan: a meta-analysis of randomized controlled trials[J] . Eur J Clin Phannacol,2012;68(2) :195-205.
  • 8Baumhalikel M, Boohm M. Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials[J] . Vase Health Risk Manag,2011 ;7 :391-7.
  • 9Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension[1). Vase Health Risk Manag, 20 II ; 7 : 777 -87.
  • 10De Backer G. The score model in the power study: an attempt to focus the limited resources for prevention on patients with greatest need[J]. CUIT Med Res Opin,2007 ;23(5) :SI9-24.

共引文献56

同被引文献20

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部